Register to receive presentation post-event
About This EventThe Immuno-Oncology Summit will take place August 29-September 1 in Boston, MA.
Join Victor Weigman, Director, Translational Genomics, on August 29th for his presentation, "Leveraging RNA-Seq for a Robust, Accurate Measure of HLA Calling for Endpoints in Clinical Trials".
Or, register to receive a copy of his presentation after the event.
Learn more about the Immuno-Oncology Summit on the event website.
Director, Translational Genomics
Dr. Victor Weigman, Ph.D. is Director, Translational Genomics at Q2 Solutions, a Quintiles Quest Joint Venture, leading the group with a goal of continued facilitation of pre-clinical drug development through biomarker identification. Ongoing research revolves around the genomic profiling of solid tumors from both DNA and RNA approaches including the development of robust assays that can be leveraged as laboratory developed tests.
Dr. Weigman brings more than 10 years of biomarker discovery research with genomics, with a majority of them dedicated to Expression Analysis (EA), a Q2 Solutions Company. He has published 14 papers on biomarker identification and assay development and has contributed to the development and launch of several genomic CLIA Assays. Additionally, Dr. Weigman is involved in pharma partnerships for clinical trial development using genomic profiling technologies.
Dr. Weigman obtained his Ph.D. at the University of North Carolina in Biology and Bioinformatics within the Lineberger Comprehensive Cancer Center.
Updated as of September 2018.